BioSpace News Archive

ABU DHABI, United Arab Emirates--( BUSINESS WIRE )-- Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202103080

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1 meetings with investors during the 33rd Annual Roth Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE™) for cancer, announces preclinical results for its ROR1 TriKE™ product candidate as a prospective therapy for the treatment of prostate cancer.

IsoPlexis announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry.

Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement with Shanghai-based Alpha Biopharma Inc.

ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the company’s T-cell-based COVID-19 vaccine candidate, hAd5.

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,

Production of monoclonal antibodies targeting these sites is in process. U.S. patent protection has been filed claiming these sites.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 and 2031 (the “notes”) in an unregistered offering, subject to market conditions.